ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 64 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,288 | +13.3% | 2,126 | +104.0% | 0.00% | – |
| Q2 2023 | $9,964 | +38.4% | 1,042 | +62.3% | 0.00% | – |
| Q1 2023 | $7,199 | -10.0% | 642 | +18.5% | 0.00% | – |
| Q4 2022 | $8,000 | -11.1% | 542 | +18.6% | 0.00% | – |
| Q3 2022 | $9,000 | -18.2% | 457 | 0.0% | 0.00% | – |
| Q2 2022 | $11,000 | +37.5% | 457 | +14.2% | 0.00% | – |
| Q1 2022 | $8,000 | 0.0% | 400 | 0.0% | 0.00% | – |
| Q4 2021 | $8,000 | -55.6% | 400 | -45.2% | 0.00% | – |
| Q3 2021 | $18,000 | -76.0% | 730 | -73.6% | 0.00% | – |
| Q2 2021 | $75,000 | +257.1% | 2,764 | +291.5% | 0.00% | – |
| Q1 2021 | $21,000 | -93.8% | 706 | -94.1% | 0.00% | -100.0% |
| Q4 2020 | $336,000 | +2700.0% | 11,961 | +2890.2% | 0.00% | – |
| Q3 2020 | $12,000 | 0.0% | 400 | 0.0% | 0.00% | – |
| Q2 2020 | $12,000 | 0.0% | 400 | 0.0% | 0.00% | – |
| Q1 2020 | $12,000 | – | 400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 8,684,232 | $46,113,272 | 3.06% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,105,309 | $5,869,191 | 2.34% |
| Bain Capital Life Sciences Investors, LLC | 3,000,000 | $15,930,000 | 1.78% |
| Sio Capital Management, LLC | 635,969 | $3,376,995 | 1.04% |
| Rubric Capital Management LP | 5,034,530 | $26,733,354 | 1.00% |
| Tejara Capital Ltd | 309,179 | $1,641,740 | 0.93% |
| AlphaCentric Advisors LLC | 165,000 | $876,150 | 0.50% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,135,227 | $6,028,055 | 0.33% |
| Orbimed Advisors | 1,914,479 | $10,165,883 | 0.22% |
| Two Seas Capital LP | 164,807 | $875,125 | 0.18% |